Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase-1 study evaluating the safety, tolerability, and pharmacokinetics of single and multiple-ascending doses of SUDO-550 in healthy volunteers

Next Previous
Trial Profile

A phase-1 study evaluating the safety, tolerability, and pharmacokinetics of single and multiple-ascending doses of SUDO-550 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SUDO 550 (Primary)
  • Indications Neurodegenerative disorders
  • Focus Adverse reactions; First in man

Most Recent Events

  • 28 Oct 2025 Results published in the Sudo Biosciences Media Release
  • 03 Dec 2024 New trial record
  • 02 Dec 2024 According to a Sudo Biosciences media release, first participants have been dosed in this trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top